Raesedo is delivering a revolutionary class of asthma therapeutics. Within the lungs, surfactant protein-A (SP-A) is a naturally occurring protein that is the first line of defense when encountering viral, allergen or environmental irritants. RaeSedo has identified a 10-20 amino acid sequence that can reproduce the activity of full-length SP-A in reducing inflammation, mucus, and airway constriction associated with asthma. Our goal is to develop a replacement therapy using this novel endogenous protein.